Scott M. Pittman has reported new warrants for Nuo Therapeutics, Inc., a significant development that could impact the company's future growth. The filing reveals that Pittman acquired two types of warrants, which may enhance his stake in the company and reflect his confidence in its prospects.
Nuo Therapeutics, Inc. is classified under the SIC code for Surgical & Medical Instruments & Apparatus. The company, which operates under the ticker symbol AURX, is based in Houston, Texas. This filing is part of a series of recent disclosures, with the latest being on October 6, 2026.
The filing indicates that Pittman acquired 4,500 shares through a Second Restated Warrant and an additional 458 shares through a Prepayment Restated Warrant, both with an exercise price of $1.50 per share. The warrants were issued in connection with a funding commitment and are set to expire on January 23, 2031. Following these transactions, Pittman directly owns a total of 4,958 shares.
This development may affect various stakeholders, including investors, company management, and competitors in the surgical and medical instruments sector. Pittman’s increased ownership could signal to investors that he believes in the company's potential for growth and success.
The filing does not specify what actions will follow this transaction, leaving uncertainty about Nuo Therapeutics' next steps.